Spark Impact

Diagnostic Healthcare Ltd is a diagnostic imaging company based in Altrincham, UK, specializing in a range of medical imaging services. The company operates a network of centers and mobile units across the UK, providing services such as MRI scans, obstetric ultrasounds, bone density scans, cardiac testing, and health screenings. Diagnostic Healthcare caters to both public and private customers, offering end-to-end integrated solutions that can be delivered through mobile units or located within hospitals, general practitioner surgeries, or dedicated community sites. The leadership team includes managing director Liat Karni and chairman Michael Ringart, who guide the company's mission to deliver comprehensive diagnostic services.

Cytox Limited is focused on developing products and services aimed at addressing neurodegenerative disorders, particularly Alzheimer's disease (AD). The company specializes in cellular and genetic assays that facilitate the diagnosis and treatment of AD, leveraging the cell division cycle theory of its pathogenesis. It has created a genetic-based blood test designed for early-stage risk assessment and diagnosis of Alzheimer's disease. Cytox also offers biomarker and drug-screening services to pharmaceutical companies engaged in clinical trials for AD and mild cognitive impairment treatments. By collaborating with Affymetrix, a part of Thermo Fisher Scientific, Cytox supports the development of novel therapeutics aimed at combating this growing condition, which currently affects millions worldwide. Founded in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox serves a global clientele that includes pharmaceutical and biotechnology firms, as well as research laboratories.

Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal. We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas. This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide. Having achieved proof of concept in humans, Renephra is raising £400k to conduct device development study and design feasability.

Ai2 Ltd, a biotechnology company, develops anti-infective peptide technology based on the amino acid sequence of a segment of the human protein, Apo lipoprotein E. These peptides exhibit potent broad-spectrum activity against Gram positive and Gram-negative bacteria, fungi, and viruses including resistance strains. Its technology has several applications in healthcare and personal care areas, such as in ophthalmic, oral care, advanced wound care, personal care, and medical devices. The company was founded in 2004 and is based in Manchester, United Kingdom.